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Misfolded proteins accumulating in several neurodegenerative diseases (including Alzheimer,
Parkinson, and Huntington diseases) can cause aggregation of their native counterparts through
a mechanism similar to the infectious prion protein’s induction of a pathogenic conformation
onto its cellular isoform. Evidence for such a prion-like mechanism has now spread to the main
misfolded proteins, SOD1 and TDP-43, implicated in amyotrophic lateral sclerosis (ALS). The major
neurodegenerative diseases may therefore have mechanistic parallels for non-cell-autonomous
spread of disease within the nervous system.Neurodegenerative disorders, such as Parkinson, Huntington,
and Alzheimer diseases, frontotemporal lobar degeneration
(FTLD), and amyotrophic lateral sclerosis (ALS) are associated
with the accumulation of misfolded proteins both inside and
outside of neuronal and glial cells in the central nervous system.
Although the major protein component of the pathological
aggregations is characteristic for each neurodegenerative
disease (such as a-synuclein in Parkinson, huntingtin in Hunting-
ton, or Ab in Alzheimer disease), several proteins misfold and
accumulate in multiple diseases (especially TDP-43, which
misaccumulates in ALS, FTLD, and many other conditions).
Conversely, neurodegenerative conditions can be associated
with the presence of more than one accumulated protein (such
as Ab and tau in Alzheimer disease). These misfolded protein
aggregates are pathological hallmarks of each disease.
One widely held view is that these aggregates play a vital
role in disease initiation and progression, with the misfolded
versions of endogenous proteins likely to acquire toxic pro-
perties, potentially through increased hydrophobicity and/or
sequestration of essential cellular components within the aggre-
gates, generation of oxidative species, proteasome inhibition,
and other pathways (reviewed in Ilieva et al., 2009). An alternative
view is that the large aggregates detected immunohistochemi-
cally represent not the toxic species but the final product of
a defensive cell response aimed at protecting cells from more
toxic oligomeric species that remain undetectable by most
techniques.
Prions and Prion-like Phenomena in Neurodegeneration
Prion diseases or transmissible spongiform encephalopathies
are a class of neurodegenerative diseases that, as their name
suggests, can be transmitted from individual to individual
through ingestion or internalization of contaminated material
(reviewed in Aguzzi et al., 2008). The nature of the infectious
agent and the transmission mechanism in prion diseases have
been the subject of intense interest since the demonstration,498 Cell 147, October 28, 2011 ª2011 Elsevier Inc.45 years ago, of transmissibility of human prions (Gajdusek
et al., 1966). It is now widely accepted that the prion, the infec-
tious agent of prion diseases, consists of misfolded form(s)—
designated PrPSc—of a normal protein, the cellular prion protein
or PrPC, as was proposed by Prusiner in the early 1980s
(Prusiner, 1982). With the amplification of infectious prions
in vitro (Castilla et al., 2005) and most recently their production
from purified recombinant protein (Wang et al., 2010), the
evidence for the protein-only prion model is now overwhelming.
Prions replicate by recruiting PrPC in the ordered PrPSc-con-
taining aggregates and by inducing a pathological conformation
on the native endogenous prion protein. Although such replica-
tion/transmission mechanisms were long thought to be uniquely
associated with transmissible prion diseases, in the past decade
an increasing list of neurodegenerative (and other) diseases have
been shown to include ‘‘prion-like’’ phenomena (Table 1). We
use the term ‘‘prion-like’’ to describe molecular events that share
similarities with the infectious cycle of the mammalian prion
protein’s self-perpetuating seeded aggregation and spreading.
Beyond infectious prions, the notion of prion-like spreading of
misfolded conformations of proteins linked to human neurode-
generative diseases arose from demonstration of Ab plaque
formation in the brains of primates after injection of brain extracts
of human Alzheimer patients (Baker et al., 1994). Prion-like
spread was then established by the work of Jucker and Walker,
whose groups showed that Ab aggregation is hastened by the
presence of preformed Ab aggregates or ‘‘seeds’’ in vivo. In
particular, they showed that intracerebral injection of brain
extracts from autopsy material of human Alzheimer disease
patients or from aged Alzheimer diseasemodel mice—both con-
taining ordered aggregates of human Ab—into transgenic mice
expressing human amyloid precursor protein (APP) accelerated
the aggregation of human Ab produced as a proteolytic fragment
of transgene-encoded APP (Kane et al., 2000; Meyer-Luehmann
et al., 2006). They further showed that although peripheral routes
of inoculation, such as intravenous, oral, or intranasal, are
Table 1. Prion-like Phenomena in Neurodegenerative Diseases
Native
Protein
Aggregated
Protein or
Peptide
Main Associated
Diseases in humans
Acquired by
Infection in
Humans
Subcellular Localization Seeded Aggregation Cell-to-Cell Spreading
Inducible Clinical Disease
in Mice
Native Aggregates In Vitro
in Cell
Culture
In Vivo
in Mice
in Cell
Culture
In Vivo
in Mice
Synthetic
Seed Brain Extract
PrPC PrPSc (variant, introgenic)
Creutzfeldt-Jacob, Kuru
yes plasma
membrane
anchored
mostly
extracellular
yes yes yes yes yes yes yes
(sporadic, familial)
Creutzfeldt-Jacob,
Fatal familial insomnia,
Gerstmann-Straussler
Scheinker
no
Tau Tau frontotemporal lobar
dementia, Alzheimer
no cytoplasmic cytoplasmic yes yes yes yes yes n.d. no
a-synuclein a-synuclein Parkinson, lewy body
dementia
no nuclear and
synaptic
cytoplasmic yes yes yes yes yes n.d. yes
(acceleration
in mutant
mice)
APP b-amyloid Alzheimer no transmembrane mostly
extracellular
yes yes yes no yes no no
Huntingtin PolyQ Huntington no nuclear nuclear yes yes n.d. yes n.d. n.d. n.d.
Ataxins spinocerebellar ataxias no
SOD1 SOD1 amyotrophic lateral sclerosis no cytoplasmic cytoplasmic yes yes n.d. yes n.d. n.d. n.d.
TDP-43 TDP-43 amyotrophic lateral sclerosis,
frontotemporal lobar
degeneration
no nuclear mostly
cytoplasmic
yes yes n.d. n.d. n.d. n.d. n.d.
FUS/TLS FUS/TLS amyotrophic lateral sclerosis,
frontotemporal lobar
degeneration
no nuclear mostly
cytoplasmic
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Summary of current evidence on seeded aggregation, spreading, and clinical disease induced in experimental animals by injection of aggregated proteins associated with human neurodegen-
erative diseases. We note that ‘‘no’’ signifies that there is currently no evidence supporting the respective events.
PrPC: cellular prion protein, PrPSc: pathologic prion protein, Tau: microtubule-associated protein, PolyQ: polyglutamine, APP: amyloid precursor protein, SOD1: superoxide dismutase 1, TDP-43:
TAR DNA-binding protein 43, FUS/TLS: fused in sarcoma, translocated in liposarcoma, n.d.: not done.
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generally inefficient in seeding Ab aggregation (Eisele et al.,
2009), intraperitoneal administration of Ab-containing extracts
induced aggregation in the vicinity of brain blood vessels (Eisele
et al., 2010) that is reminiscent of cerebral b-amyloid angiopathy
associated with Alzheimer disease in humans (Thal et al., 2008).
Following a similar paradigm, intracerebral injection of mutant
tau aggregate-containing brain extracts seedwidespread aggre-
gation of normal human tau in transgenic mice that do not other-
wise develop aggregates (Clavaguera et al., 2009). Spreading
and in vivo seeding of a-synuclein aggregation was first shown
by induction of a-synuclein inclusions (also called Lewy bodies)
within normal neuronal stem cells transplanted in Parkinson
disease patients (Kordower et al., 2008; Li et al., 2008), a para-
digm that has been replicated in mice (Desplats et al., 2009;
Hansen et al., 2011). Most recently, acceleration of both aggre-
gation and, most importantly, clinical disease was shown in
transgenic mice expressing human mutant a-synuclein, after
intracerebral injection of brain extracts from old mice of the
same transgenic line (Mougenot et al., 2011). Although there is
currently no experimental evidence that expanded polyglut-
amine (polyQ) proteins can seed aggregation in animals, seeding
and persistent, self-perpetuating cell-to-cell transmission of
polyQ aggregation have been shown in cultured cells (Ren
et al., 2009). In fact, a-synuclein (Desplats et al., 2009; Hansen
et al., 2011; Nonaka et al., 2010) and tau (Frost et al., 2009;
Guo and Lee, 2011; Nonaka et al., 2010) also exhibit this seeding
behavior in cultured cells. Most recently, fibrils formed from pure
recombinant wild-type a-synuclein were shown to induce
pathological aggregates of endogenous a-synuclein in primary
neurons (Volpicelli-Daley et al., 2011). The propagation of the
above misfolded proteins in cultured cells once again resembles
PrPSc, which was initially shown to replicate in cells over 40 years
ago, a feature that has been exploited to establish a quantitative
cell-based assay for determination of infectious prion titers
(Klo¨hn et al., 2003; Mahal et al., 2007).
Except for PrPSc in prion disease, there is currently no
evidence that the other induced aggregates can spread between
individuals to cause acquired disease, either in humans or in
experimental animals. The latter might be due to the challenges
in modeling human neurodegenerative diseases in transgenic
animals, which typically do not reproduce the full pathology or
clinical disease seen in humans (Jucker, 2010). Nevertheless,
this crucial difference led Aguzzi to propose the term prionoid
to distinguish prion-like phenomena spreading disease within
a single organism from bona fide infectious prions (Aguzzi,
2009; Aguzzi and Rajendran, 2009). This is an important distinc-
tion, with the difference between prions and prionoids probably
lying in the potency of induced aggregation and spreading,
rather than any difference in underlying molecular events. This
augmented potency of prions to induce transmissible disease
may be dependent on (but not restricted to) their remarkable
resistance to endogenous proteases and other routes of path-
ogen elimination (Shorter and Lindquist, 2005).
Regardless, the prion-like replication that occurs within
affected cells followed by transfer from cell to cell provides a
molecular pathway for disease spreadwithin the nervous system
following focal generation of an initiating misfolding event.
Indeed, the apparent spreading of pathologic changes has500 Cell 147, October 28, 2011 ª2011 Elsevier Inc.been described for all the major neurodegenerative diseases,
including Alzheimer (Braak and Braak, 1991), Parkinson (Braak
et al., 2003), FTLD (Kril and Halliday, 2011), Huntington (Deng
et al., 2004), ALS (Ravits et al., 2007a, 2007b), and of course
prion diseases, where in acquired cases caused by infection,
the initial site of propagation may occur outside the central
nervous system (Aguzzi et al., 2008).
The Major Misfolded Proteins in ALS
ALS is a neurodegenerative condition that targets primarily
motor neurons, resulting in progressive paralysis and death
within a few years from onset. Just like Alzheimer, Parkinson,
and other neurodegenerative diseases, a proportion (10%) of
ALS is dominantly inherited, with the remaining 90% (referred
to as sporadic) of unknown origin. The identification in 1993 of
mutation in the gene encoding superoxide dismutase 1 (SOD1)
as the first or second most common form of inherited ALS
(Rosen et al., 1993), and subsequent generation of transgenic
mice expressing ALS-causing mutants in SOD1, initiated the
molecular era of deciphering disease mechanism. A flurry of
approaches established that non-cell-autonomous disease
depends on one or more toxic properties of mutant SOD1. The
latter drives disease initiation when synthesized within motor
neurons, whereas its synthesis by glial neighbors provokes rapid
disease advance (reviewed in Ilieva et al., 2009). Along with
prion-infected mice, the ALS-linked mutant SOD1 mice are
among the most faithful models of neurodegeneration, recapitu-
lating the selective progressive loss of motor neurons that leads
to the paralysis characteristic of human ALS.
In both inherited and sporadic ALS, affected neurons and
glial cells contain abnormal proteinaceous accumulations, often
labeled by anti-ubiquitin antibodies. The major protein compo-
nent of these accumulations in familial cases with SOD1 muta-
tions—and in mutant SOD1 mice—is SOD1 itself. An initial
view that SOD1 inclusions were not found in sporadic disease,
e.g., Kerman et al. (2010), has recently been challenged (Bosco
et al., 2010; Forsberg et al., 2010). This controversy notwith-
standing, over the past 5 years it has been established that
a main component of proteinaceous cytoplasmic inclusions in
essentially all sporadic ALS cases is the RNA/DNA-binding
protein TDP-43, accompanied by its nuclear depletion (Arai
et al., 2006; Neumann et al., 2006). Moreover, mutations in
TDP-43 are causes of inherited ALS and rare instances of
FTLD (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan
et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008).
Affected neurons of patients with TDP-43 mutations also
develop cytoplasmic TDP-43-positive inclusions and nuclear
loss, implying that abnormal localization and aggregation of
TDP-43 could represent a first mechanistic link between
sporadic ALS and an inherited form caused by a known muta-
tion. Furthermore, ALS-causing mutations were identified in
a gene encoding another RNA/DNA-binding protein, called
FUS/TLS for fused in sarcoma or translocated in liposarcoma
(Kwiatkowski et al., 2009; Vance et al., 2009). FUSmutant-medi-
ated disease is also accompanied by FUS/TLS-containing
cytoplasmic inclusions and disturbed subcellular localization.
Unresolved is whether pathogenesis in TDP-43- or FUS/TLS-
mediated disease results from a loss of nuclear function of either
protein, from a gain of toxic property or properties associated
(or not) with their cytoplasmic inclusions, or—perhaps most
likely—from a combination of all possibilities.
Aggregation Initiation of ALS-Associated Proteins
Within the last year, a plausible, unifying proposal for underlying
disease mechanism among the inherited and sporadic ALS
instances has emerged: normal SOD1, TDP-43, and possibly
also FUS/TLS can undergo seeded aggregation that can spread
from cell to cell through a prion-like mechanism after an initiating
event.
SOD1 is a small 153 amino acid protein, which in its native
state occurs as a remarkably stable dimer that is highly resistant
to proteolytic degradation. ALS-associated point mutations
occur in almost every position (>140 mutations are known) with
each leading to destabilization and eventually accumulation of
misfolded species within affected cells of the nervous system.
In vitro studies with purified SOD1 have shown that both the
wild-type and several mutant versions of the protein spontane-
ously form fibrils under denaturing conditions (Chia et al.,
2010; Grad et al., 2011; Mu¨nch et al., 2011; Prudencio et al.,
2009), with a propensity to aggregate that is enhanced in the
mutants (Chia et al., 2010; Prudencio et al., 2009).
TDP-43 consists of two RNA-recognition motifs and a largely
disorganized C-terminal domain that contains the overwhelming
majority of ALS-associated mutations (reviewed in Lagier-Tour-
enne et al., 2010). This C-terminal region of TDP-43 was sus-
pected to play a critical role in ALS pathogenesis as early anal-
yses revealed that it is the main proteolytic fragment
(designated CTF) identified in the cytoplasmic inclusions of
sporadic patients (Arai et al., 2006; Igaz et al., 2008; Neumann
et al., 2006). This same region was proposed to contain a gluta-
mine/asparagine-rich (Q/N-rich) domain that shares similarities
with what have been called yeast prions (Cushman et al., 2010;
Fuentealba et al., 2010), proteins that exhibit ordered, self-
perpetuating aggregation and that are transmissible from an
affected cell to its progeny (reviewed in Chien et al., 2004; Cush-
man et al., 2010; Shorter and Lindquist, 2005). The known yeast
prion domains can switch their conformation between two
states: an intrinsically unfolded one and an aggregated one
that imposes its conformation to its unfolded counterpart.
Like SOD1, TDP-43 and TDP-43-derived peptides form aggre-
gates in vitro (Furukawa et al., 2011; Guo et al., 2011; Johnson
et al., 2008, 2009), and ALS-causing mutations enhance this
behavior (Guo et al., 2011; Johnson et al., 2009). Highlighting
its critical role for TDP-43 aggregation, the C-terminal region of
TDP-43 is apparently indispensable for aggregation (Furukawa
et al., 2011; Johnson et al., 2008, 2009), and truncation mutants
consisting solely of TDP-43 CTF show significantly increased
aggregation propensities in vitro and in cells (Furukawa et al.,
2011; Guo et al., 2011; Johnson et al., 2008, 2009; Liu-Yesuce-
vitz et al., 2010). Importantly, the C-terminal region of TDP-43
acquires partial resistance to proteases when packaged within
full-length TDP-43 aggregates (Furukawa et al., 2011; Guo
et al., 2011), a property reminiscent of the pathogenic PrPSc.
Collectively, these data suggest that aggregation of TDP-43 is
driven by its prion-like C-terminal region and that ALS-linked
mutations are likely to promote this process.The 526 amino acid FUS/TLS is structurally and functionally
related to TDP-43 (Lagier-Tourenne et al., 2010). The ALS-
causing mutations are mainly shared between the very last
part of the protein containing its nuclear localization signal
(NLS) (Dormann et al., 2010; Ito et al., 2011; Sun et al., 2011)
and an 100 amino acid glycine-rich domain. The latter is incor-
porated within a predicted Q/N-rich, yeast prion-like domain
comprising the first 239 amino acids of FUS/TLS (Cushman
et al., 2010). Purified FUS/TLS was shown to aggregate
extremely rapidly—within a few minutes—in a cell-free system
under native conditions and without the agitation (Sun et al.,
2011) typically used to facilitate protein aggregation in vitro
(Furukawa et al., 2011; Guo et al., 2011; Wang et al., 2010).
Compared to TDP-43 and SOD1, FUS/TLS demonstrates the
highest aggregation propensity, but this property is not affected
by ALS-causing mutations localized in its NLS (Dormann et al.,
2010; Sun et al., 2011). Rather, these mutations clearly enhance
the cytoplasmic accumulation/retention of FUS/TLS (Dormann
et al., 2010; Ito et al., 2011). Increased cytoplasmic FUS/TLS in
cultured neurons seems to eventually translate into increased
aggregation that promotes its integration into foci called stress
granules that are comprised of RNA and RNA-binding proteins
and that form in response to several known stresses (Anderson
and Kedersha, 2009). On the other hand, mutations residing in
the prion-like domain of FUS/TLS do not enhance its cyto-
plasmic localization or its integration within stress granules
(Dormann et al., 2010) but may directly increase its aggregation
propensity (Figure 1A).
Although SOD1, TDP-43, and FUS/TLS readily aggregate
in vitro, the intracellular array of protein-folding chaperones
must act to inhibit this. So, what triggers the initiation of aggrega-
tion in disease and the selective vulnerability of the most highly
affected nervous system regions? These remain two of the
most important unresolved questions in ALS (and neurodegener-
ative disease in general). The natural decline of proteostatic
mechanisms that occurs with aging has been widely proposed
to mediate the pathogenic process, with mutations likely to tip
the balance by increasing the aggregation propensity of the
respective proteins. In agreement with this, aggregation propen-
sities of SOD1 mutants and the degree of cytoplasmic mislocal-
ization of NLS mutants of FUS/TLS inversely correlate with the
age of disease onset of familial ALS patients (Dormann et al.,
2010; Prudencio et al., 2009). For sporadic disease, yet unde-
fined environmental and/or genetic triggers may converge to
initiate the pathogenic process. In line with this view, recent
work from cell-culture systems has suggested that a combina-
tion of two insults or ‘‘two hits’’ is required for the formation of
pathologic cytoplasmic inclusions of both FUS/TLS and TDP-
43. For FUS/TLS, the two hits are cytoplasmic localization and
cell stress (Dormann et al., 2010), whereas for TDP-43, they
are cleavage of the CTF and disruption of microtubule transport
(Pesiridis et al., 2011).
Self-Propagated Aggregation of ALS-Associated
Proteins
A very provocative finding implicating a self-propagating spread
for both SOD1 and TDP-43 emerged within the last year, initially
from demonstrations that aggregated forms of either can seedCell 147, October 28, 2011 ª2011 Elsevier Inc. 501
Figure 1. Prion-like Phenomena in Amyotrophic Lateral Sclerosis
(A) Mutant, misfolded superoxide dismutase 1 (SOD1) induces the misfolding of its native counterpart, in a template-directed reaction, thereby forming a seed of
aggregated protein. TDP-43 and FUS/TLS (mutant andwild-type) are both incorporated in stress granules, which form through the ordered aggregation of several
RNA-binding proteins complexed with RNA molecules. This physiologic reaction to cellular stress may be the initial trigger for pathogenic inclusion formation
given that the increased local protein concentration and RNA scaffolding molecules may facilitate ordered aggregation of TDP-43 and/or FUS/TLS. Mutations in
the prion-like domain of TDP-43 (and maybe also FUS/TLS) enhance its aggregation propensity, whereas mutations in the nuclear localization domain (NLS) of
FUS/TLS increase its cytoplasmic localization.
(B) Misfolded SOD1 follows a self-perpetuating seeding reaction in cell culture. Upon chronic cellular stress and defects in stress granule disassembly occurring
with aging, the functional prion-like conformational changes of TDP-43 and FUS/TLS associated with their physiological roles in stress granule formation may
transform into pathogenic self-perpetuating, irreversible aggregation. It is unknownwhether cellular RNA is occasionally trapped within the cytoplasmic FUS/TLS
and/or TDP-43 inclusions, thereby depleting the cell of essential RNA components.
(C) SOD1 aggregates transfer from cell to cell to initiate misfolding and aggregation of native SOD1 in neighboring cells (shown in cell culture). It is currently not
known whether TDP-43 and/or FUS/TLS can spread from cell to cell by a similar mechanism.
Filled blue boxes on TDP-43 and FUS/TLS molecules indicate RNA-recognition motifs, and the lighter blue box on FUS/TLS refers to the zinc finger domain that
can also bind RNA.misfolding of a much larger amount of the corresponding wild-
type protein in vitro (Chia et al., 2010; Furukawa et al., 2011).
Moreover, in cultured cells, misfolded forms of both SOD1 and502 Cell 147, October 28, 2011 ª2011 Elsevier Inc.TDP-43, either exogenously applied (Furukawa et al., 2011;
Mu¨nch et al., 2011) or formed within cells (Grad et al., 2011;
Pesiridis et al., 2011), induced the misfolding and subsequent
aggregation of the respective native proteins. Importantly,
induced aggregation of endogenous SOD1was shown to persist
after removal of the misfolded seeds (Grad et al., 2011; Mu¨nch
et al., 2011), suggesting that the newly formed aggregates can
act as templates for the subsequent misfolding of additional
native SOD1 (Figure 1B). This behavior is consistent with
a self-perpetuating, cyclic reaction, analogous to that underlying
the replication of infectious prion aggregates. Although it
remains to be determined whether FUS/TLS aggregation can
be seeded, the implication of both TDP-43 and FUS/TLS in
stress granule assembly (Andersson et al., 2008; Colombrita
et al., 2009; Ito et al., 2011; Liu-Yesucevitz et al., 2010;
McDonald et al., 2011; Moisse et al., 2009; Wang et al., 2008)
offers a plausiblemechanism for aggregation initiation and seed-
ing as a response to a variety of cellular stresses (Figure 1B).
Indeed, the very formation of stress granules is mediated by
the ordered aggregation of TIA1, an integral stress granule
protein component that possesses a Q/N-rich yeast prion-like
domain (Gilks et al., 2004). Seeded aggregation of TIA1 through
its prion-like domain seems to be the driving force of stress
granule formation, as this domain is not only indispensable
for TIA1’s nucleation, but it can even be replaced by another
Q/N-rich domain from a yeast prion protein (SUP35) without
visibly affecting the size or number of stress granules (Gilks
et al., 2004). Aggregated TIA1 within cytoplasmic foci recruits
mRNAs and other proteins, including TDP-43 and FUS/TLS
(Andersson et al., 2008; Colombrita et al., 2009; Ito et al., 2011;
Liu-Yesucevitz et al., 2010; McDonald et al., 2011; Moisse
et al., 2009; Wang et al., 2008).
Because increased protein concentration is expected to be
a main determinant for protein aggregation, the increase of local
TDP-43 and FUS/TLS concentration within stress granules could
facilitate the initiation of their aggregation. This may be further
assisted by the presence of RNA that can act as a scaffolding
molecule mediating the ordered aggregation of TDP-43 and
FUS/TLS within these cytoplasmic foci. Indeed, the scaffolding
capacity of RNA has been established in the in vitro aggregation
of the mammalian prion protein (Deleault et al., 2003), as gener-
ation of infectious prions with purified PrP has been achieved
only by the addition of RNA and phospholipids (Wang et al.,
2010). Whereas for the in vitro aggregation of PrP, the RNA is
likely to mimic other, yet unknown cellular factors, in the case
of RNA-binding proteins like TDP-43 and FUS/TLS, intimate
interaction with RNA in stress granules may represent an early
stage of inclusion formation actually occurring in neurons and
glial cells.
In healthy cells, stress granule formation (and TIA1 aggrega-
tion) is dynamically regulated and reversible (Kedersha et al.,
2000). In fact, TIA1 belongs to a group of proteins that undergo
reversible, conformational switches leading to self-replicating
aggregation, which confers a functional advantage for the aggre-
gate-bearing cells and their neighbors (Shorter and Lindquist,
2005). The notion of such functional prion-like proteins was first
shown in yeast, where several proteins, including SUP35 intro-
duced above, were found to provide different functional roles
before and after aggregation in yeast cells (reviewed in Uptain
and Lindquist, 2002). The list of such proteins is expanding,
and besides TIA1 and yeast prions, it currently includes the cyto-plasmic polyadenylation element binding protein (CPEB), whose
ordered aggregation has been proposed to facilitate long-term
memory (Si et al., 2010; Si et al., 2003), and most recently,
MAVS, a signaling protein that forms mitochondrial membrane-
associated aggregates that trigger an RNA-dependent response
to viral infection (Hou et al., 2011).
In this context, we hypothesize that the functional conforma-
tional changes of TDP-43 and FUS/TLS associated with their
physiological roles in stress granule formation may transform
into pathogenic, self-perpetuating, irreversible aggregation
upon chronic cellular stress and defects in stress granule disas-
sembly occurring with aging (Figure 1B). In other words, stress
granules may be operating to facilitate FUS/TLS and/or TDP-
43 ‘‘seeding’’ within the cytoplasm of diseased cells. The obser-
vation that stress granule proteins partition in the TDP-43 and
FUS/TLS pathologic inclusions found in ALS patients supports
this view (Dormann et al., 2010; Fujita et al., 2008; Liu-Yesucevitz
et al., 2010).
Unresolved is whether specific cellular RNAs are sequestered
within the cytoplasmic FUS/TLS and/or TDP-43 inclusions,
thereby depleting the cell of essential RNA components. The
latter, if true, could explain the observation that although the
RNA-recognition motifs of TDP-43 are not required for its aggre-
gation (Johnson et al., 2008; Pesiridis et al., 2011), binding to
RNA seems to be indispensible for its cytotoxicity (Elden et al.,
2010; Voigt et al., 2010).
Mutant-Wild-Type Interactions of ALS-Associated
Proteins
Template-directed misfolding refers to the conversion of a
natively folded protein into a misfolded version of itself through
direct interaction with another misfolded molecule. Such
template-directed misfolding seems to occur between wild-
type (native) and mutant (misfolded) proteins in ALS. Indeed,
misfolded SOD1 has been shown to induce the misfolding of
native, wild-type SOD1 (Figure 1A) in cultured cells (Grad et al.,
2011), andmutant-wild-type coaggregates were found in familial
ALS patients (Bruijn et al., 1998), a finding replicated in mice
coexpressing normal and mutant human SOD1 (Deng et al.,
2006). These complexes are likely pathogenic, as coexpression
of human wild-type SOD1—which by itself is nonpathogenic in
mice even when accumulated to >5 times the level of endoge-
nous SOD1—sharply accelerates disease onset and progression
in mice from expression of various ALS-linked mutants (Deng
et al., 2006). Moreover, neuron-specific expression of mutant
SOD1 in mice causes dramatic aggregation in glial cells of
wild-type SOD1 expressed from an ubiquitously active promoter
(Jaarsma et al., 2008).
In this context, wild-type human SOD1-overexpressing mice
may represent an ideal case for testing the in vivo seeding
activity of misfolded SOD1 in a paradigm similar to those used
for Ab (Clavaguera et al., 2009; Meyer-Luehmann et al., 2006;
Mougenot et al., 2011), tau (Clavaguera et al., 2009; Meyer-
Luehmann et al., 2006; Mougenot et al., 2011), and a-synuclein
(Clavaguera et al., 2009; Meyer-Luehmann et al., 2006; Mouge-
not et al., 2011). Because wild-type human SOD1 neither causes
disease nor aggregates in the absence of mutants, a crucial test
will now be to determine whether injection of preformedCell 147, October 28, 2011 ª2011 Elsevier Inc. 503
aggregated SOD1 seeds can trigger aggregation and, if so, clin-
ical disease.
Dissimilar primary sequences between themisfolded template
and the endogenous native protein substrate dramatically affect
the efficiency of the template-directed misfolded reaction, as
evidenced by transmission barriers of infectious prions from
different species (reviewed in Aguzzi et al., 2008). Consistent
with this is the observation that human misfolded SOD1 is not
a competent template for mouse SOD1, which was attributed
to a single amino acid difference between the human and mouse
protein position 32 (Grad et al., 2011), pointing to a likely interact-
ing region for this conformational conversion. This finding
explains the inactive role of mouse SOD1 in human mutant
SOD1 transgenic mice, which neither affects any aspect of
disease course (Bruijn et al., 1998) nor coaggregates with the
human mutant protein (Deng et al., 2006).
What about mutant-wild-type interactions of TDP-43 and
FUS/TLS? The cytoplasmic inclusions of TDP-43 or FUS/TLS
that are accompanied by reduction of nuclear levels in ALS
patients with dominant mutations in either protein strongly
suggest that the wild-type isoforms are incorporated within the
inclusions (assuming that expression of the wild-type allele is
not silenced in these cells). The sustained expression of TDP-
43 and FUS/TLS in aged motor neurons (Huang et al., 2010)
may partially explain their selective vulnerability, as they provide
a continuous substrate for misfolding and seeding of toxic
aggregates. The latter may be further exacerbated by an autor-
egulation mechanism controlling TDP-43 levels (Ayala et al.,
2011; Igaz et al., 2011; Polymenidou et al., 2011), which may
feed-forward the seeding by elevated synthesis of new TDP-
43, as more and more existing protein is incorporated into the
growing aggregates.
Cross-seeding Phenomena
In some cases, aggregated proteins can act as heterologous
templates inducing the misfolding and aggregation of other
dissimilar proteins, a phenomenon referred to as cross-seeding.
So, is there any evidence for cross-seeding among themain ALS
proteins? Early reports argued against the coexistence of aggre-
gated forms of the different ALS-associated proteins, with SOD1
and FUS/TLS restricted in the respective familial ALS cases
bearing mutations in each protein and TDP-43 dominating the
inclusions of sporadic ALS and familial cases with TDP-43
mutations. This is now controversial: some recent studies have
reported the presence of wild-type misfolded SOD1 (Bosco
et al., 2010; Forsberg et al., 2010) and FUS/TLS (Deng
et al., 2010) in sporadic ALS inclusions. The reported misfolded
SOD1 inclusions were found to be distinct from ones containing
TDP-43, whereas FUS/TLS was claimed to colocalize with
aggregated TDP-43 in sporadic ALS patients.We note, however,
that in vitro and cell-culture studies do not support cross-seed-
ing interactions between SOD1 and TDP-43 (Furukawa et al.,
2011) or TDP-43 and FUS/TLS (Dormann et al., 2010; Ito et al.,
2011; Sun et al., 2011).
Unexpectedly, TDP-43 and FUS/TLS can both be cross-
seeded in cultured cells by polyQ aggregates, through a mecha-
nism that depends on the Q/N-rich prion-like domains of TDP-43
and FUS/TLS (Fuentealba et al., 2010). In fact, proteins with504 Cell 147, October 28, 2011 ª2011 Elsevier Inc.Q/N-rich prion-like domains may be generally suitable sub-
strates for polyQ aggregations, as more such proteins (for
example, TIA1) were found sequestered in these inclusions
(Furukawa et al., 2009). The relevance of these cross-seeding
events for human disease is highlighted by the colocalization
of TDP-43 and FUS/TLSwith polyQ aggregates found in patients
with Huntington disease (Doi et al., 2008; Schwab et al., 2008;
Woulfe et al., 2010) or spinocerebellar ataxia (Doi et al., 2010;
Elden et al., 2010; Woulfe et al., 2010). The observation that
TDP-43 and FUS/TLS aggregation occurs in many neurodegen-
erative diseases (summarized in Lagier-Tourenne et al., 2010),
with occasional colocalization with other aggregated proteins,
may represent unidentified cross-seeding reactions among the
major misfolded proteins driving neurodegeneration. Further
in vitro and in vivo studies are needed to clarify the extent of
cross-seeding phenomena in ALS and other neurodegenerative
diseases.
Glia-to-Neuron Toxic Spread in ALS
It is now well established that a released or secreted toxic factor
produced by astrocytes ormicrogliamediates the killing ofmotor
neurons in ALS-like disease in mutant SOD1 mice, a mechanism
that was shown to drive rapid disease progression (Boille´e
et al., 2006; Yamanaka et al., 2008). This has been replicated
in vitro: cocultures of mutant SOD1 glial cells with normal motor
neurons—both mouse and human—have shown that toxicity
can be transferred from mutant to normal cells through an
unidentified factor(s) present in the media (Di Giorgio et al.,
2007, 2008; Marchetto et al., 2008; Nagai et al., 2007). Most
recently, the in vivo toxicity of mutant SOD1-expressing astro-
cytes was confirmed by the transplantation of astrocyte progen-
itor cells in wild-type mice. In this paradigm, the grafted glial
progenitor cells matured into mutant SOD1-expressing astro-
cytes and induced motor neuron death in the spinal cords of
wild-type mice (Papadeas et al., 2011).
Most provocatively, evidence for spreading of SOD1-depen-
dent toxicity as a general feature of human ALS has just
appeared from cocultures of neural progenitor cell-derived
astrocytes either from ALS patients with disease caused by an
SOD1 mutant or—in a finding that will astonish many in the
neurodegenerative disease community—from seven out of
seven sporadic ALS patients as well. To establish this, Kaspar
and colleagues (Haidet-Phillips et al., 2011) recovered neural
progenitor cells from eight ALS autopsy samples (seven
sporadic and one with a SOD1A4V mutation) and then differenti-
ated them in vitro into astrocytes. Direct coculture of normal
mouse motor neurons with these astrocytes, or conditioned
media derived from these, was found to be toxic to the neurons.
Of even higher impact, siRNA knockdown of SOD1 in astrocytes
eliminated the toxicity, demonstrating that the production of
a released factor(s) that is toxic to motor neurons is mediated
through glial SOD1 synthesis.
One obvious possibility—whose test is now of highest impor-
tance for decoding disease mechanism in ALS—is that toxicity
is transferred through a yet unidentified, misfolded SOD1 seed
that may trigger prion-like aggregation of normal SOD1 in
neighboring cells (Figure 1C). Indeed, mutant SOD1 has been
proposed to be actively secreted with neurosecretory vesicles
through an aberrant interaction with chromogranins A and B
(Urushitani et al., 2006), and exogenously applied SOD1
aggregates have been shown to enter cells through macropino-
cytosis (Mu¨nch et al., 2011). A cautionary note, however: the
transfer of toxicity from human astrocytes to mouse motor
neurons in the Haidet-Phillips et al. (2011) work argues against
toxicity from SOD1-seeded aggregation and spreading, given
that mouse SOD1 is apparently not a substrate for human
SOD1 seeds (Grad et al., 2011; Mu¨nch et al., 2011), as explained
above.
Neurodegeneration in ALS typically begins focally and then
spreads spatiotemporally until the loss of the motor neurons of
the respiratory system (Ravits et al., 2007a, 2007b). An attractive
model for this progression of disease would be spreading of
toxic aggregates from a focal site. Consequently, dissecting
the molecular determinants of these processes may facilitate
the construction of therapeutic agents that could interfere with
disease progression.
Crucial Tests Now Needed in ALS
Going forward, among the most crucial goals in ALS is confirma-
tion—with replication by other teams—of the proposed SOD1-
dependent, astrocyte-driven toxicity that may be common
to sporadic and familial ALS. So too are extensions to test
whether TDP-43 or FUS/TLS plays any role in this astrocyte-
mediated toxicity. With the increasing appreciation of the role
of template-directed misfolding and seeded aggregation of
ALS-associated proteins, the flurry of lessons learned and tools
established by the prion field may become valuable for future
studies in ALS. One example is to exploit protein misfolding
cyclic amplification (PMCA) (Castilla et al., 2005; Wang et al.,
2010), initially used to amplify pathogenic prions in vitro, and
which could now be used to test the potential interplay between
different proteins in seeded aggregation in ALS.
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